Bank Julius Baer & Co. Ltd Zurich Takes $701,000 Position in Natera, Inc. (NASDAQ:NTRA)

Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,959 shares of the medical research company's stock, valued at approximately $701,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. HighPoint Advisor Group LLC raised its position in shares of Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock worth $308,000 after buying an additional 468 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Natera by 9.8% in the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after purchasing an additional 740 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after purchasing an additional 207 shares in the last quarter. Teza Capital Management LLC bought a new stake in shares of Natera in the 4th quarter worth approximately $221,000. Finally, Asset Management One Co. Ltd. bought a new stake in shares of Natera in the 1st quarter worth approximately $6,753,000. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 339 shares of the stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $139.29, for a total transaction of $47,219.31. Following the sale, the insider owned 153,460 shares of the company's stock, valued at $21,375,443.40. This represents a 0.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,622 shares of the stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $139.29, for a total transaction of $225,928.38. Following the sale, the chief executive officer directly owned 175,492 shares in the company, valued at approximately $24,444,280.68. This represents a 0.92% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,844 shares of company stock worth $7,488,466. 7.60% of the stock is currently owned by company insiders.

Natera Stock Performance

Shares of Natera stock traded down $0.17 on Monday, reaching $138.73. The stock had a trading volume of 303,757 shares, compared to its average volume of 1,488,898. The business's 50-day moving average price is $158.80 and its two-hundred day moving average price is $156.85. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock has a market cap of $18.94 billion, a P/E ratio of -94.26 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.56) EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NTRA. Piper Sandler boosted their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. UBS Group boosted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Evercore ISI began coverage on shares of Natera in a report on Monday. They issued an "outperform" rating and a $170.00 target price on the stock. Barclays boosted their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Finally, Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.